Clinical Trials List
2017-09-01 - 2028-12-31
Phase III
Terminated11
ICD-10C50
Malignant neoplasm of breast
ICD-10C79.81
Secondary malignant neoplasm of breast
ICD-9233.0
Carcinoma in situ of breast
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- MING-YANG WANG Division of General Surgery
- 張端瑩 Division of Hematology & Oncology
- 蔡立威 Division of General Surgery
- 林季宏 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- YEN-SHEN LU Division of Hematology & Oncology
- 楊雅雯 Division of General Surgery
- 郭文宏 Division of General Surgery
- SUNG-HSIN KUO Division of Hematology & Oncology
- 羅喬 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
- Yao-Chung Wu Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- Chen-Teng Wu Division of General Surgery
- Chih-Jung Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Fang-Ming Chen Division of Gastroenterological Surgery
- Fu Ouyang Division of Gastroenterological Surgery
- 甘蓉瑜 Division of Gastroenterological Surgery
- Chieh-Han Chuang Division of Gastroenterological Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 陳彥仰 Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- Yu-Li Su Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 陳宇欽 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 廖國秀 Division of General Surgery
- 張平穎 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
- 何景良 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 許桓銘 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Ta-Chung Chao Division of Radiation Therapy
- Yi-Fang Tsai Division of General Surgery
- 金光亮 Division of General Surgery
- 林永慧 Division of Radiology
- Chun-Yu Liu Division of Radiation Therapy
- 林燕淑 Division of General Surgery
- 邱仁輝 Division of General Surgery
The Actual Total Number of Participants Enrolled
11 Stop recruiting
Audit
None
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
Audit
None
Co-Principal Investigator
- Tsu-Yi Chao Division of Hematology & Oncology
- 蘇勇誠 Division of Hematology & Oncology
- Wei-Hong Cheng Division of Hematology & Oncology
- KA-WAI TAM Division of General Surgery
- Yao-Yu Hsieh Division of Hematology & Oncology
- 蘇智銘 Division of General Surgery
- Wei-Hwa Lee Division of Others -
- TSU-YI CHAO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
8 Stop recruiting
Audit
None
Taiwan National PI
Co-Principal Investigator
- Chi-Chang Yu Division of General Surgery
- Wen-Chi Shen Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- 周旭桓 Division of General Surgery
- 沈士哲 Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
- Hsien-Kun Chang Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
16 Stop recruiting
Audit
None
Co-Principal Investigator
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
144 participants
-
Global
4580 participants
